PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Wenqiang Mo

First Affiliated Hospital of Shihezi University Medical College

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 13, 2026 · JOURNAL ARTICLE

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study

Frontiers in Oncology

Single-center retrospective study showing superior PFS and ORR for ICI+chemotherapy versus bevacizumab+chemotherapy in driver gene-negative NSCLC, but limited by retrospective design, unbalanced group sizes, and lack of adjustment for confounders.

PromisingJing Fei Lung Cancer Treatments and Mutations Yinzhen Li

Reported

Median PFS (ICIs+chemotherapy)14.330 months

Median PFS (bevacizumab+chemother…9.60 months

PFS p-value0.014

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support